ENDOCRINE TUMORS:BRAFV600E mutations in papillary craniopharyngioma

Successful Treatment of a ProgressiveBRAFV600E–Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy

(2016) Eudocia Q. Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Topographic Diagnosis of Papillary Craniopharyngiomas: The Need for an Accurate MRI-Surgical Correlation

(2015) J.M. Pascual et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With BRAFV600E-Mutated Erdheim-Chester Disease

(2015) Julien Haroche et al.   JOURNAL OF CLINICAL ONCOLOGY

BRAF V600E mutation is a useful marker for differentiating Rathke’s cleft cyst with squamous metaplasia from papillary craniopharyngioma

(2015) Jang-Hee Kim et al.   JOURNAL OF NEURO-ONCOLOGY

Adamantinomatous craniopharyngioma: pathology, molecular genetics and mouse models

(2015) Juan Pedro Martinez-Barbera et al.   JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM

Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy

(2015) Priscilla K. Brastianos et al.   JNCI-Journal of the National Cancer Institute

Survival, hypothalamic obesity, and neuropsychological/psychosocial status after childhood-onset craniopharyngioma: newly reported long-term outcomes

(2015) Anthe S. Sterkenburg et al.   NEURO-ONCOLOGY

Molecular and cellular pathogenesis of adamantinomatous craniopharyngioma

(2015) Juan Pedro Martinez-Barbera   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

BRAF V600Eanalysis for the differentiation of papillary craniopharyngiomas and Rathke's cleft cysts

(2015) Leonille Schweizer et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

(2015) David M. Hyman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor

(2015) Simon J. B. Aylwin et al.   Pituitary

Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy

(2015) Priscilla K. Brastianos et al.   JNCI-Journal of the National Cancer Institute

BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma

(2014) Sarah Jane Larkin et al.   ACTA NEUROPATHOLOGICA

VE1 Antibody Immunoreactivity in Normal Anterior Pituitary and Adrenal Cortex Without Detectable BRAF V600E Mutations

(2014) Daniel A. Mordes et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Pretreatment Diagnosis of Suprasellar Papillary Craniopharyngioma and Germ Cell Tumors of Adult Patients

(2014) H.-J. Lee et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Outcome and mid-term prognosis after maximum and radical removal of craniopharyngiomas with the priority to the extended transsphenoidal approach—A single center experience

(2014) Yoshikazu Ogawa et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

Food intake regulating hormones in adult craniopharyngioma patients

(2014) J Roemmler-Zehrer et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Sleep–wake and melatonin pattern in craniopharyngioma patients

(2014) Line Pickering et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Morbidity of repeat transsphenoidal surgery assessed in more than 1000 operations

(2014) Arman Jahangiri et al.   JOURNAL OF NEUROSURGERY

Progress towards personalized medicine for ameloblastoma

(2014) Carolina C Gomes et al.   JOURNAL OF PATHOLOGY

Clinical and Radiographic Response With Combined BRAF-Targeted Therapy in Stage 4 Ameloblastoma

(2014) F. J. Kaye et al.   JNCI-Journal of the National Cancer Institute

Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of cilia

(2014) Robert T Jones et al.   MODERN PATHOLOGY

Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas

(2014) Priscilla K Brastianos et al.   NATURE GENETICS

Identification of recurrent SMO and BRAF mutations in ameloblastomas

(2014) Robert T Sweeney et al.   NATURE GENETICS

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011

(2014) Q. T. Ostrom et al.   NEURO-ONCOLOGY

Patterns of Care for Craniopharyngioma: Survey of Members of the American Association of Neurological Surgeons

(2014) Todd C. Hankinson et al.   PEDIATRIC NEUROSURGERY

Hairy cell leukemia: short review, today’s recommendations and outlook

(2014) V Maevis et al.   Blood Cancer Journal

Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade

(2014) Z. A. Cooper et al.   Cancer Immunology Research

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation

(2013) F. Peyrade et al.   HAEMATOLOGICA

Rapid Response to Vemurafenib in a Heavily Pretreated Patient With Hairy Cell Leukemia and a BRAF Mutation

(2013) Javier Munoz et al.   JOURNAL OF CLINICAL ONCOLOGY

Continued Response Off Treatment After BRAF Inhibition in Refractory Hairy Cell Leukemia

(2013) Sascha Dietrich et al.   JOURNAL OF CLINICAL ONCOLOGY

Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series

(2013) Marc C. Chamberlain   JOURNAL OF NEURO-ONCOLOGY

Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations

(2013) Priscilla K Brastianos et al.   NATURE GENETICS

Tight junction protein claudin-1 is differentially expressed in craniopharyngioma subtypes and indicates invasive tumor growth

(2013) Christina Stache et al.   NEURO-ONCOLOGY

Rapid response of biallelicBRAFV600E mutated hairy cell leukaemia to low dose vemurafenib

(2012) George A. Follows et al.   BRITISH JOURNAL OF HAEMATOLOGY

Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR

(2012) Hans Bösmüller et al.   HUMAN PATHOLOGY

BRAF Inhibition in Refractory Hairy-Cell Leukemia

(2012) Sascha Dietrich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Craniopharyngioma: history

(2012) Garni Barkhoudarian et al.   Pituitary

Infundibulo-tuberal or not strictly intraventricular craniopharyngioma: evidence for a major topographical category

(2011) José M. Pascual et al.   ACTA NEUROCHIRURGICA

Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody

(2011) David Capper et al.   ACTA NEUROPATHOLOGICA

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

(2011) James S. Wilmott et al.   CLINICAL CANCER RESEARCH

Management of recurrent craniopharyngioma

(2011) Simon V. Liubinas et al.   JOURNAL OF CLINICAL NEUROSCIENCE

BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications

(2011) Dora Dias-Santagata et al.   PLoS One

Increased Wingless (Wnt) signaling in pituitary progenitor/stem cells gives rise to pituitary tumors in mice and humans

(2011) C. Gaston-Massuet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Craniopharyngioma and other cystic epithelial lesions of the sellar region: a review of clinical, imaging, and histopathological relationships

(2010) Gabriel Zada et al.   Neurosurgical Focus

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples

(2009) Laura E. MacConaill et al.   PLoS One